Ali Fattaey
Chief Executive Officer at Metabomed Ltd.
Profile
Ali Fattaey is the founder of ACT Biotech, Inc. which was founded in 2008.
He was the President & Chief Operating Officer from 2013 to 2014.
Currently, he is the Chief Executive Officer at Metabomed Ltd.
since 2020.
Previously, he worked as the President, Chief Executive Officer & Director at Curis, Inc. from 2013 to 2018.
He was also the Director-Science & Technology at Melanoma Therapeutics Foundation from 2006 to 2008.
He was a Director at EpiTherapeutics ApS and a Senior Vice President-Discovery Research at Chiron Corp.
He worked as the Vice President-Discovery Research at Onyx Pharmaceuticals, Inc. from 1994 to 2001 and as the Chief Scientific Officer at Sagres Discovery, Inc. from 2001 to 2004.
He also worked as a Research Fellow at Harvard Medical School.
He received his doctorate degree from Kansas State University in 1989.
Ali Fattaey active positions
| Companies | Position | Start |
|---|---|---|
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Chief Executive Officer | 2020-09-08 |
Former positions of Ali Fattaey
| Companies | Position | End |
|---|---|---|
| CURIS, INC. | Chief Executive Officer | 2018-09-23 |
ACT Biotech, Inc.
 ACT Biotech, Inc. Pharmaceuticals: MajorHealth Technology ACT Biotech, Inc. operates as a biopharmaceutical company which develops and commercializes targeted oral cancer drugs. The company was founded on February 15, 2008 and is headquartered in New York, NY. | Chief Executive Officer | 2014-05-31 |
Melanoma Therapeutics Foundation
 Melanoma Therapeutics Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Therapeutics Foundation supports and researches treatments for melanoma. It provides resources for patients and physicians, supports investigators, and provides new drug development through bridging relationships between academia, pharmaceutical and biotechnology companies. The foundation is headquartered in San Francisco, California | Corporate Officer/Principal | 2007-12-31 |
Sagres Discovery, Inc.
 Sagres Discovery, Inc. Pharmaceuticals: MajorHealth Technology Sagres Discovery, Inc. researches and discovers oncology treatments. Its technology platform combines the biology of cancer formation in mouse models with the robustness of genomic technologies to enable discovery and clinical validation of human cancer genes. The company is headquartered in Davis, CA. | Chief Tech/Sci/R&D Officer | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 2001-05-31 |
Training of Ali Fattaey
| Kansas State University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Sagres Discovery, Inc.
Sagres Discovery, Inc. Pharmaceuticals: MajorHealth Technology Sagres Discovery, Inc. researches and discovers oncology treatments. Its technology platform combines the biology of cancer formation in mouse models with the robustness of genomic technologies to enable discovery and clinical validation of human cancer genes. The company is headquartered in Davis, CA. | Health Technology |
ACT Biotech, Inc.
ACT Biotech, Inc. Pharmaceuticals: MajorHealth Technology ACT Biotech, Inc. operates as a biopharmaceutical company which develops and commercializes targeted oral cancer drugs. The company was founded on February 15, 2008 and is headquartered in New York, NY. | Health Technology |
Melanoma Therapeutics Foundation
Melanoma Therapeutics Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Therapeutics Foundation supports and researches treatments for melanoma. It provides resources for patients and physicians, supports investigators, and provides new drug development through bridging relationships between academia, pharmaceutical and biotechnology companies. The foundation is headquartered in San Francisco, California | Commercial Services |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Health Technology |
- Stock Market
- Insiders
- Ali Fattaey
